LAG3 PET Imaging in Advanced Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 18, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Metastatic Solid Tumor

Interventions

OTHER

89Zr-DFO-REGN3767

Anti-LAG-3 PET imaging tracer

DRUG

Cemiplimab

Cemiplimab 350 mg every 3 weeks with or without platinum-based chemotherapy.

Trial Locations (1)

University Medical Center Groninen, Groningen

All Listed Sponsors

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

University Medical Center Groningen

OTHER

NCT04706715 - LAG3 PET Imaging in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter